Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2003 Oct 28;169(9):921-4.

Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update

Jacques Genest  1 , Jiri Frohlich, George Fodor, Ruth McPherson; Working Group on Hypercholesterolemia and Other Dyslipidemias
Affiliations
Comment

Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update

Jacques Genest et al. CMAJ. .

Erratum in

  • CMAJ. 2003 Nov 25;169(11):1149
No abstract available

PubMed Disclaimer

Comment in

  • Dyslipidemia guidelines.
    Levyman C. Levyman C. CMAJ. 2004 Jul 20;171(2):118; author reply 118-9. doi: 10.1503/cmaj.1031819. CMAJ. 2004. PMID: 15262866 Free PMC article. No abstract available.
  • Dyslipidemia guidelines.
    Hindle HR. Hindle HR. CMAJ. 2004 Jul 20;171(2):118; author reply 118-9. doi: 10.1503/cmaj.1031820. CMAJ. 2004. PMID: 15262868 Free PMC article. No abstract available.
  • Questioning the benefits of statins.
    Vos E, Rose CP. Vos E, et al. CMAJ. 2005 Nov 8;173(10):1207; author reply 1210. doi: 10.1503/cmaj.1050120. CMAJ. 2005. PMID: 16275976 Free PMC article. No abstract available.
  • Questioning the benefits of statins.
    Mazowita G. Mazowita G. CMAJ. 2005 Nov 8;173(10):1210; author reply 1210. doi: 10.1503/cmaj.1050121. CMAJ. 2005. PMID: 16275979 Free PMC article. No abstract available.

Comment on

References

    1. Fodor JG, Frohlich JJ, Genest JJG Jr, McPherson PR, for the Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management and treatment of dyslipidemia: report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. CMAJ 2000;162(10):1441-7. - PMC - PubMed
    1. Grundy SM, Becker D, Clark LT, on behalf of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Bethesda (MD): National Institutes of Health; 2002. Available: www.nhlbi.nih.gov/guidelines/cholesterol/index.htm (accessed 2003 Sept 26).
    1. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al, on behalf of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285(13):1711-8. - PubMed
    1. Robins SJ, Collins D, Rubins HB. Relation of baseline lipids and lipid changes with gemfibrozil to cardiovascular endpoints in VA-High-Density Lipoprotein Intervention Trial (VA-HIT). Circulation 1999;100(18)(Suppl I):I-238.
    1. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22. - PubMed